You are here

FDA Rejects Kidney Cancer Drug Tivozanib

Pivotal data deemed ‘uninterpretable’ (June 10)

The FDA has declined to approve the new drug application (NDA) for tivozanib (Aveo Pharmaceuticals), an investigational tyrosine kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC).

In its complete response letter (CRL), the agency stated that the inconsistent progression-free and overall survival results and the imbalance in post-study treatments make the results of the pivotal TIVO-1 (TIvozanib Versus SOrafenib in 1st Line Advanced RCC) trial uninterpretable and inconclusive when making a risk-benefit assessment necessary for drug approval. The agency recommended that an additional clinical study be conducted to support approval of tivozanib for the treatment of advanced RCC.

The FDA also stated that the proposed dissolution acceptance criterion was not supported by the provided dissolution data, and would need to be updated and resubmitted.

Source: Aveo Pharmaceuticals; June 10, 2013.

Recent Headlines

New drug addresses bacterial resistance to standard therapy
Hovering flights lower packages by cable and winch
Ziextenzo helps lower the incidence of febrile neutropenia
The answer may offer a potential treatment for the disease
Drug resistance in HIV patients has nearly tripled since 2001
Drug resistance in HIV patients has nearly tripled since 2001
The number of those with an annual drug spend of $250K or more has increased by 60%
Grading manufacturers would give high-quality, reliable makers a boost, says federal panel
Sharpless is heading back to NCI